The scientific basis of combination therapy for chronic hepatitis B functional cure-Reference-Cited by-同舟云学术

The scientific basis of combination therapy for chronic hepatitis B functional cure

Published:2023-01-11 Issue:4 Volume:20 Page:238-253
ISSN:1759-5045
Container-title:Nature Reviews Gastroenterology & Hepatology
language:en
Short-container-title:Nat Rev Gastroenterol Hepatol

Author:

Lim Seng Gee^ORCID,Baumert Thomas F.^ORCID,Boni Carolina,Gane Ed,Levrero Massimo,Lok Anna S.,Maini Mala K.^ORCID,Terrault Norah A.,Zoulim Fabien^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Hepatology

Link

https://www.nature.com/articles/s41575-022-00724-5.pdf

Reference179 articles.

1. World Health Organization. Hepatitis B Fact Sheet, https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (2021).

2. Cornberg, M. et al. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology https://doi.org/10.1002/hep.31030 (2019).

3. Fanning, G. C., Zoulim, F., Hou, J. & Bertoletti, A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat. Rev. Drug Discov. 18, 827–844 (2019).

4. Anderson, R. T. et al. Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 19, 463–472 (2021).

5. Lok, A. S. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63, 284–306 (2016).

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mice Engrafted with Human Liver Cells;Seminars in Liver Disease;2024-09-12

2. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B;Antiviral Research;2024-09

3. Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect;European Journal of Medicinal Chemistry;2024-09

4. Serum IP-10 increase correlated with PEG-IFNα response in nucleot(s)ide analogs-treated patients with chronic hepatitis B;iLIVER;2024-09

5. Improved preclinical drug metabolism and pharmacokinetics of pibothiadine (HEC121210), a novel hepatitis B virus capsid assembly modulator;Xenobiotica;2024-08-12